nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.357	0.691	CbGbCtD
Bortezomib—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.159	0.309	CbGbCtD
Bortezomib—Motor dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00832	0.0341	CcSEcCtD
Bortezomib—Subdural haematoma—Riluzole—amyotrophic lateral sclerosis	0.00576	0.0236	CcSEcCtD
Bortezomib—Pneumonia aspiration—Riluzole—amyotrophic lateral sclerosis	0.00553	0.0227	CcSEcCtD
Bortezomib—Panophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.00495	0.0203	CcSEcCtD
Bortezomib—Peritonitis—Riluzole—amyotrophic lateral sclerosis	0.00478	0.0196	CcSEcCtD
Bortezomib—Angina unstable—Riluzole—amyotrophic lateral sclerosis	0.00478	0.0196	CcSEcCtD
Bortezomib—PSMA1—embryo—amyotrophic lateral sclerosis	0.00449	0.0622	CbGeAlD
Bortezomib—Faecaloma—Riluzole—amyotrophic lateral sclerosis	0.00423	0.0173	CcSEcCtD
Bortezomib—Faecalith—Riluzole—amyotrophic lateral sclerosis	0.00423	0.0173	CcSEcCtD
Bortezomib—Skin mass—Riluzole—amyotrophic lateral sclerosis	0.00389	0.016	CcSEcCtD
Bortezomib—Nephritis—Riluzole—amyotrophic lateral sclerosis	0.00353	0.0145	CcSEcCtD
Bortezomib—Disseminated intravascular coagulation—Riluzole—amyotrophic lateral sclerosis	0.00338	0.0138	CcSEcCtD
Bortezomib—PSMD2—embryo—amyotrophic lateral sclerosis	0.00334	0.0462	CbGeAlD
Bortezomib—Dementia—Riluzole—amyotrophic lateral sclerosis	0.00294	0.0121	CcSEcCtD
Bortezomib—Cheilitis—Riluzole—amyotrophic lateral sclerosis	0.00284	0.0116	CcSEcCtD
Bortezomib—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.00279	0.0114	CcSEcCtD
Bortezomib—Thrombocytopenic purpura—Riluzole—amyotrophic lateral sclerosis	0.00257	0.0105	CcSEcCtD
Bortezomib—Proctalgia—Riluzole—amyotrophic lateral sclerosis	0.00257	0.0105	CcSEcCtD
Bortezomib—Hernia—Riluzole—amyotrophic lateral sclerosis	0.00257	0.0105	CcSEcCtD
Bortezomib—PSMB1—embryo—amyotrophic lateral sclerosis	0.00256	0.0355	CbGeAlD
Bortezomib—Endophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.00254	0.0104	CcSEcCtD
Bortezomib—PSMB2—embryo—amyotrophic lateral sclerosis	0.0025	0.0346	CbGeAlD
Bortezomib—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00994	CcSEcCtD
Bortezomib—Muscle relaxant therapy—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00994	CcSEcCtD
Bortezomib—PSMD1—medulla oblongata—amyotrophic lateral sclerosis	0.00241	0.0333	CbGeAlD
Bortezomib—Faecal incontinence—Riluzole—amyotrophic lateral sclerosis	0.00239	0.0098	CcSEcCtD
Bortezomib—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00966	CcSEcCtD
Bortezomib—Hypotonia—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00941	CcSEcCtD
Bortezomib—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00893	CcSEcCtD
Bortezomib—PSMA1—nervous system—amyotrophic lateral sclerosis	0.00215	0.0298	CbGeAlD
Bortezomib—PSMD1—spinal cord—amyotrophic lateral sclerosis	0.00215	0.0297	CbGeAlD
Bortezomib—PSMD2—medulla oblongata—amyotrophic lateral sclerosis	0.00213	0.0295	CbGeAlD
Bortezomib—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00872	CcSEcCtD
Bortezomib—PSMA1—central nervous system—amyotrophic lateral sclerosis	0.00207	0.0287	CbGeAlD
Bortezomib—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00841	CcSEcCtD
Bortezomib—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00831	CcSEcCtD
Bortezomib—PSMA1—cerebellum—amyotrophic lateral sclerosis	0.00203	0.0281	CbGeAlD
Bortezomib—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00813	CcSEcCtD
Bortezomib—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00787	CcSEcCtD
Bortezomib—PSMD2—spinal cord—amyotrophic lateral sclerosis	0.0019	0.0263	CbGeAlD
Bortezomib—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00779	CcSEcCtD
Bortezomib—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00779	CcSEcCtD
Bortezomib—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00779	CcSEcCtD
Bortezomib—PSMB5—medulla oblongata—amyotrophic lateral sclerosis	0.00187	0.0259	CbGeAlD
Bortezomib—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00755	CcSEcCtD
Bortezomib—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00181	0.0074	CcSEcCtD
Bortezomib—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00726	CcSEcCtD
Bortezomib—Seborrhoeic dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00726	CcSEcCtD
Bortezomib—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00719	CcSEcCtD
Bortezomib—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00712	CcSEcCtD
Bortezomib—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00712	CcSEcCtD
Bortezomib—Ileus—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00699	CcSEcCtD
Bortezomib—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00699	CcSEcCtD
Bortezomib—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00699	CcSEcCtD
Bortezomib—PSMD1—cerebellum—amyotrophic lateral sclerosis	0.0017	0.0236	CbGeAlD
Bortezomib—PSMB5—spinal cord—amyotrophic lateral sclerosis	0.00167	0.0231	CbGeAlD
Bortezomib—PSMA1—brain—amyotrophic lateral sclerosis	0.00165	0.0228	CbGeAlD
Bortezomib—PSMB1—medulla oblongata—amyotrophic lateral sclerosis	0.00164	0.0227	CbGeAlD
Bortezomib—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00668	CcSEcCtD
Bortezomib—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00662	CcSEcCtD
Bortezomib—PSMD2—nervous system—amyotrophic lateral sclerosis	0.0016	0.0222	CbGeAlD
Bortezomib—PSMB2—medulla oblongata—amyotrophic lateral sclerosis	0.0016	0.0221	CbGeAlD
Bortezomib—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00646	CcSEcCtD
Bortezomib—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00635	CcSEcCtD
Bortezomib—PSMD2—central nervous system—amyotrophic lateral sclerosis	0.00154	0.0214	CbGeAlD
Bortezomib—PSMD2—cerebellum—amyotrophic lateral sclerosis	0.00151	0.0209	CbGeAlD
Bortezomib—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00615	CcSEcCtD
Bortezomib—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00615	CcSEcCtD
Bortezomib—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00601	CcSEcCtD
Bortezomib—PSMB1—spinal cord—amyotrophic lateral sclerosis	0.00146	0.0202	CbGeAlD
Bortezomib—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00597	CcSEcCtD
Bortezomib—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00583	CcSEcCtD
Bortezomib—PSMB2—spinal cord—amyotrophic lateral sclerosis	0.00142	0.0197	CbGeAlD
Bortezomib—Delirium—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00575	CcSEcCtD
Bortezomib—SLC31A1—medulla oblongata—amyotrophic lateral sclerosis	0.00138	0.0192	CbGeAlD
Bortezomib—PSMD1—brain—amyotrophic lateral sclerosis	0.00138	0.0192	CbGeAlD
Bortezomib—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00548	CcSEcCtD
Bortezomib—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00544	CcSEcCtD
Bortezomib—PSMB5—cerebellum—amyotrophic lateral sclerosis	0.00132	0.0183	CbGeAlD
Bortezomib—Gout—Riluzole—amyotrophic lateral sclerosis	0.00129	0.0053	CcSEcCtD
Bortezomib—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00526	CcSEcCtD
Bortezomib—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00523	CcSEcCtD
Bortezomib—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00523	CcSEcCtD
Bortezomib—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00507	CcSEcCtD
Bortezomib—SLC31A1—spinal cord—amyotrophic lateral sclerosis	0.00123	0.0171	CbGeAlD
Bortezomib—PSMB1—nervous system—amyotrophic lateral sclerosis	0.00123	0.017	CbGeAlD
Bortezomib—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00504	CcSEcCtD
Bortezomib—PSMD2—brain—amyotrophic lateral sclerosis	0.00122	0.017	CbGeAlD
Bortezomib—PSMB8—brain—amyotrophic lateral sclerosis	0.00122	0.0169	CbGeAlD
Bortezomib—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00495	CcSEcCtD
Bortezomib—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00495	CcSEcCtD
Bortezomib—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00495	CcSEcCtD
Bortezomib—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00495	CcSEcCtD
Bortezomib—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00492	CcSEcCtD
Bortezomib—PSMB2—nervous system—amyotrophic lateral sclerosis	0.0012	0.0166	CbGeAlD
Bortezomib—PSMB1—central nervous system—amyotrophic lateral sclerosis	0.00118	0.0164	CbGeAlD
Bortezomib—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00483	CcSEcCtD
Bortezomib—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00478	CcSEcCtD
Bortezomib—PSMB1—cerebellum—amyotrophic lateral sclerosis	0.00116	0.016	CbGeAlD
Bortezomib—PSMB2—central nervous system—amyotrophic lateral sclerosis	0.00116	0.016	CbGeAlD
Bortezomib—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00472	CcSEcCtD
Bortezomib—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00115	0.0047	CcSEcCtD
Bortezomib—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00464	CcSEcCtD
Bortezomib—PSMB2—cerebellum—amyotrophic lateral sclerosis	0.00113	0.0156	CbGeAlD
Bortezomib—Coma—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00452	CcSEcCtD
Bortezomib—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00447	CcSEcCtD
Bortezomib—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00447	CcSEcCtD
Bortezomib—PSMB5—brain—amyotrophic lateral sclerosis	0.00108	0.0149	CbGeAlD
Bortezomib—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00107	0.0044	CcSEcCtD
Bortezomib—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00429	CcSEcCtD
Bortezomib—SLC31A1—nervous system—amyotrophic lateral sclerosis	0.00104	0.0144	CbGeAlD
Bortezomib—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00421	CcSEcCtD
Bortezomib—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00417	CcSEcCtD
Bortezomib—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00413	CcSEcCtD
Bortezomib—SLC31A1—central nervous system—amyotrophic lateral sclerosis	0.001	0.0139	CbGeAlD
Bortezomib—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00098	0.00401	CcSEcCtD
Bortezomib—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00098	0.00401	CcSEcCtD
Bortezomib—SLC31A1—cerebellum—amyotrophic lateral sclerosis	0.000978	0.0135	CbGeAlD
Bortezomib—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.000966	0.00396	CcSEcCtD
Bortezomib—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.000945	0.00387	CcSEcCtD
Bortezomib—PSMB1—brain—amyotrophic lateral sclerosis	0.00094	0.013	CbGeAlD
Bortezomib—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.000933	0.00382	CcSEcCtD
Bortezomib—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.000933	0.00382	CcSEcCtD
Bortezomib—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.000925	0.00379	CcSEcCtD
Bortezomib—Thirst—Riluzole—amyotrophic lateral sclerosis	0.000921	0.00377	CcSEcCtD
Bortezomib—PSMB2—brain—amyotrophic lateral sclerosis	0.000917	0.0127	CbGeAlD
Bortezomib—Purpura—Riluzole—amyotrophic lateral sclerosis	0.000909	0.00372	CcSEcCtD
Bortezomib—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.000902	0.00369	CcSEcCtD
Bortezomib—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.000898	0.00368	CcSEcCtD
Bortezomib—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00088	0.0036	CcSEcCtD
Bortezomib—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.000876	0.00359	CcSEcCtD
Bortezomib—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.000876	0.00359	CcSEcCtD
Bortezomib—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000876	0.00359	CcSEcCtD
Bortezomib—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00087	0.00356	CcSEcCtD
Bortezomib—Migraine—Riluzole—amyotrophic lateral sclerosis	0.000863	0.00353	CcSEcCtD
Bortezomib—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.000856	0.00351	CcSEcCtD
Bortezomib—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000849	0.0118	CbGeAlD
Bortezomib—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.000846	0.00347	CcSEcCtD
Bortezomib—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.000833	0.00341	CcSEcCtD
Bortezomib—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.000833	0.00341	CcSEcCtD
Bortezomib—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.000824	0.00338	CcSEcCtD
Bortezomib—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.000815	0.00334	CcSEcCtD
Bortezomib—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.0008	0.00328	CcSEcCtD
Bortezomib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.000798	0.00327	CcSEcCtD
Bortezomib—SLC31A1—brain—amyotrophic lateral sclerosis	0.000794	0.011	CbGeAlD
Bortezomib—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.000792	0.00324	CcSEcCtD
Bortezomib—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.000776	0.00318	CcSEcCtD
Bortezomib—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000773	0.00317	CcSEcCtD
Bortezomib—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.000763	0.00312	CcSEcCtD
Bortezomib—Influenza—Riluzole—amyotrophic lateral sclerosis	0.000758	0.0031	CcSEcCtD
Bortezomib—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.000758	0.0031	CcSEcCtD
Bortezomib—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.000743	0.00304	CcSEcCtD
Bortezomib—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.000738	0.00302	CcSEcCtD
Bortezomib—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.000729	0.00298	CcSEcCtD
Bortezomib—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000726	0.00297	CcSEcCtD
Bortezomib—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.000719	0.00295	CcSEcCtD
Bortezomib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.000708	0.0029	CcSEcCtD
Bortezomib—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00287	CcSEcCtD
Bortezomib—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.000698	0.00286	CcSEcCtD
Bortezomib—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000691	0.00283	CcSEcCtD
Bortezomib—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000689	0.00282	CcSEcCtD
Bortezomib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.000685	0.00281	CcSEcCtD
Bortezomib—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000679	0.00278	CcSEcCtD
Bortezomib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.000675	0.00277	CcSEcCtD
Bortezomib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.000675	0.00277	CcSEcCtD
Bortezomib—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.000666	0.00273	CcSEcCtD
Bortezomib—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.000662	0.00271	CcSEcCtD
Bortezomib—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.000662	0.00271	CcSEcCtD
Bortezomib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.000658	0.0027	CcSEcCtD
Bortezomib—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.000657	0.00269	CcSEcCtD
Bortezomib—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.000644	0.00264	CcSEcCtD
Bortezomib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.000639	0.00262	CcSEcCtD
Bortezomib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000637	0.00261	CcSEcCtD
Bortezomib—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.000634	0.0026	CcSEcCtD
Bortezomib—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000617	0.00253	CcSEcCtD
Bortezomib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000609	0.0025	CcSEcCtD
Bortezomib—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000606	0.00248	CcSEcCtD
Bortezomib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000606	0.00248	CcSEcCtD
Bortezomib—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.000603	0.00247	CcSEcCtD
Bortezomib—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.000603	0.00247	CcSEcCtD
Bortezomib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000599	0.00245	CcSEcCtD
Bortezomib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000597	0.00245	CcSEcCtD
Bortezomib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000596	0.00244	CcSEcCtD
Bortezomib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000594	0.00243	CcSEcCtD
Bortezomib—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000573	0.00235	CcSEcCtD
Bortezomib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000567	0.00232	CcSEcCtD
Bortezomib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000563	0.0023	CcSEcCtD
Bortezomib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00055	0.00225	CcSEcCtD
Bortezomib—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000548	0.00224	CcSEcCtD
Bortezomib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000546	0.00224	CcSEcCtD
Bortezomib—Chills—Riluzole—amyotrophic lateral sclerosis	0.000544	0.00223	CcSEcCtD
Bortezomib—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000542	0.00222	CcSEcCtD
Bortezomib—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000531	0.00218	CcSEcCtD
Bortezomib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000528	0.00216	CcSEcCtD
Bortezomib—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00052	0.00213	CcSEcCtD
Bortezomib—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000517	0.00212	CcSEcCtD
Bortezomib—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000511	0.00209	CcSEcCtD
Bortezomib—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000507	0.00208	CcSEcCtD
Bortezomib—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000495	0.00203	CcSEcCtD
Bortezomib—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00049	0.00201	CcSEcCtD
Bortezomib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000488	0.002	CcSEcCtD
Bortezomib—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000486	0.00674	CbGeAlD
Bortezomib—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000485	0.00199	CcSEcCtD
Bortezomib—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000482	0.00198	CcSEcCtD
Bortezomib—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000476	0.00195	CcSEcCtD
Bortezomib—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000474	0.00194	CcSEcCtD
Bortezomib—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000473	0.00194	CcSEcCtD
Bortezomib—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000472	0.00194	CcSEcCtD
Bortezomib—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000466	0.00191	CcSEcCtD
Bortezomib—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000464	0.0019	CcSEcCtD
Bortezomib—Cough—Riluzole—amyotrophic lateral sclerosis	0.000461	0.00189	CcSEcCtD
Bortezomib—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000457	0.00187	CcSEcCtD
Bortezomib—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000456	0.00187	CcSEcCtD
Bortezomib—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000449	0.00184	CcSEcCtD
Bortezomib—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000449	0.00184	CcSEcCtD
Bortezomib—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000449	0.00184	CcSEcCtD
Bortezomib—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000448	0.00183	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000446	0.00183	CcSEcCtD
Bortezomib—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000444	0.00182	CcSEcCtD
Bortezomib—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000434	0.00178	CcSEcCtD
Bortezomib—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000431	0.00176	CcSEcCtD
Bortezomib—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000431	0.00176	CcSEcCtD
Bortezomib—Infection—Riluzole—amyotrophic lateral sclerosis	0.000428	0.00175	CcSEcCtD
Bortezomib—Shock—Riluzole—amyotrophic lateral sclerosis	0.000424	0.00174	CcSEcCtD
Bortezomib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000422	0.00173	CcSEcCtD
Bortezomib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000422	0.00173	CcSEcCtD
Bortezomib—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00042	0.00172	CcSEcCtD
Bortezomib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000418	0.00171	CcSEcCtD
Bortezomib—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000416	0.00171	CcSEcCtD
Bortezomib—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000411	0.00168	CcSEcCtD
Bortezomib—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000403	0.00165	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000392	0.00161	CcSEcCtD
Bortezomib—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00039	0.0016	CcSEcCtD
Bortezomib—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000387	0.00158	CcSEcCtD
Bortezomib—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000384	0.00157	CcSEcCtD
Bortezomib—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000379	0.00155	CcSEcCtD
Bortezomib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000374	0.00153	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000372	0.00152	CcSEcCtD
Bortezomib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000371	0.00152	CcSEcCtD
Bortezomib—Pain—Riluzole—amyotrophic lateral sclerosis	0.000368	0.00151	CcSEcCtD
Bortezomib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000368	0.00151	CcSEcCtD
Bortezomib—PTGS1—spinal cord—amyotrophic lateral sclerosis	0.000368	0.0051	CbGeAlD
Bortezomib—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000355	0.00145	CcSEcCtD
Bortezomib—CYP1A1—nervous system—amyotrophic lateral sclerosis	0.000353	0.00489	CbGeAlD
Bortezomib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000352	0.00144	CcSEcCtD
Bortezomib—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000342	0.0014	CcSEcCtD
Bortezomib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000341	0.00139	CcSEcCtD
Bortezomib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000341	0.00139	CcSEcCtD
Bortezomib—CYP1A1—central nervous system—amyotrophic lateral sclerosis	0.00034	0.00471	CbGeAlD
Bortezomib—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000317	0.0013	CcSEcCtD
Bortezomib—PTGS1—nervous system—amyotrophic lateral sclerosis	0.00031	0.00429	CbGeAlD
Bortezomib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000309	0.00127	CcSEcCtD
Bortezomib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000305	0.00125	CcSEcCtD
Bortezomib—PTGS1—central nervous system—amyotrophic lateral sclerosis	0.000298	0.00413	CbGeAlD
Bortezomib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000295	0.00121	CcSEcCtD
Bortezomib—CYP2C8—brain—amyotrophic lateral sclerosis	0.000292	0.00405	CbGeAlD
Bortezomib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000285	0.00117	CcSEcCtD
Bortezomib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000274	0.00112	CcSEcCtD
Bortezomib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000272	0.00111	CcSEcCtD
Bortezomib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000271	0.00111	CcSEcCtD
Bortezomib—Headache—Riluzole—amyotrophic lateral sclerosis	0.00027	0.00111	CcSEcCtD
Bortezomib—CYP1A1—brain—amyotrophic lateral sclerosis	0.00027	0.00374	CbGeAlD
Bortezomib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000259	0.00359	CbGeAlD
Bortezomib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000256	0.00105	CcSEcCtD
Bortezomib—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000255	0.00353	CbGeAlD
Bortezomib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000249	0.00345	CbGeAlD
Bortezomib—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000245	0.0034	CbGeAlD
Bortezomib—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.00024	0.00332	CbGeAlD
Bortezomib—PTGS1—brain—amyotrophic lateral sclerosis	0.000237	0.00328	CbGeAlD
Bortezomib—CYP2D6—brain—amyotrophic lateral sclerosis	0.000195	0.0027	CbGeAlD
Bortezomib—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.39e-05	0.000202	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—ERBB4—amyotrophic lateral sclerosis	3.34e-05	0.000199	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—ERBB4—amyotrophic lateral sclerosis	3.34e-05	0.000199	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—ERBB4—amyotrophic lateral sclerosis	3.34e-05	0.000199	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.33e-05	0.000198	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.33e-05	0.000198	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.31e-05	0.000197	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.3e-05	0.000197	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—ERBB4—amyotrophic lateral sclerosis	3.29e-05	0.000196	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	3.28e-05	0.000196	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	3.28e-05	0.000196	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	3.26e-05	0.000194	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	3.25e-05	0.000194	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	3.25e-05	0.000194	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.2e-05	0.000191	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	3.2e-05	0.00019	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.19e-05	0.00019	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.17e-05	0.000189	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—DAO—amyotrophic lateral sclerosis	3.15e-05	0.000188	CbGpPWpGaD
Bortezomib—PSMA1—Disease—APOE—amyotrophic lateral sclerosis	3.15e-05	0.000188	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD40LG—amyotrophic lateral sclerosis	3.14e-05	0.000187	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD40LG—amyotrophic lateral sclerosis	3.14e-05	0.000187	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD40LG—amyotrophic lateral sclerosis	3.14e-05	0.000187	CbGpPWpGaD
Bortezomib—PSMD1—Disease—APOE—amyotrophic lateral sclerosis	3.13e-05	0.000187	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	3.13e-05	0.000187	CbGpPWpGaD
Bortezomib—PSMD2—Disease—APOE—amyotrophic lateral sclerosis	3.12e-05	0.000186	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD40LG—amyotrophic lateral sclerosis	3.1e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB5—Disease—ERBB4—amyotrophic lateral sclerosis	3.08e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB1—Disease—ERBB4—amyotrophic lateral sclerosis	3.08e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB2—Disease—ERBB4—amyotrophic lateral sclerosis	3.08e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB8—Disease—ERBB4—amyotrophic lateral sclerosis	3.04e-05	0.000181	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.03e-05	0.000181	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.03e-05	0.000181	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	3e-05	0.000179	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	2.98e-05	0.000177	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	2.89e-05	0.000172	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	2.85e-05	0.00017	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.85e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.85e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.84e-05	0.000169	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.82e-05	0.000168	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.82e-05	0.000168	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.82e-05	0.000168	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.82e-05	0.000168	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.8e-05	0.000167	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.79e-05	0.000166	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.78e-05	0.000166	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.78e-05	0.000166	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.78e-05	0.000166	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—C3—amyotrophic lateral sclerosis	2.78e-05	0.000165	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—C3—amyotrophic lateral sclerosis	2.78e-05	0.000165	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—C3—amyotrophic lateral sclerosis	2.78e-05	0.000165	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.77e-05	0.000165	CbGpPWpGaD
Bortezomib—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.76e-05	0.000165	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—C3—amyotrophic lateral sclerosis	2.74e-05	0.000163	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.68e-05	0.00016	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.67e-05	0.000159	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.65e-05	0.000158	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.65e-05	0.000158	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.65e-05	0.000158	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.65e-05	0.000158	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.64e-05	0.000157	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.64e-05	0.000157	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.64e-05	0.000157	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—APOE—amyotrophic lateral sclerosis	2.64e-05	0.000157	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	2.62e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—APOE—amyotrophic lateral sclerosis	2.62e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.61e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—APOE—amyotrophic lateral sclerosis	2.61e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.61e-05	0.000155	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	2.6e-05	0.000155	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.59e-05	0.000154	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	2.58e-05	0.000154	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.57e-05	0.000153	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.54e-05	0.000152	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.52e-05	0.00015	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.52e-05	0.00015	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.52e-05	0.00015	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—TP53—amyotrophic lateral sclerosis	2.5e-05	0.000149	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TP53—amyotrophic lateral sclerosis	2.49e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.49e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TP53—amyotrophic lateral sclerosis	2.48e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.43e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.43e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.43e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.39e-05	0.000143	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.39e-05	0.000142	CbGpPWpGaD
Bortezomib—PSMB2—Disease—APOE—amyotrophic lateral sclerosis	2.39e-05	0.000142	CbGpPWpGaD
Bortezomib—PSMB1—Disease—APOE—amyotrophic lateral sclerosis	2.39e-05	0.000142	CbGpPWpGaD
Bortezomib—PSMB5—Disease—APOE—amyotrophic lateral sclerosis	2.39e-05	0.000142	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	2.37e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.37e-05	0.000141	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.36e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.36e-05	0.00014	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	2.35e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMB8—Disease—APOE—amyotrophic lateral sclerosis	2.35e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.35e-05	0.00014	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.35e-05	0.00014	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.22e-05	0.000132	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSR—amyotrophic lateral sclerosis	2.21e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.2e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.19e-05	0.000131	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	2.19e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.18e-05	0.00013	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.16e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.16e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.16e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMA1—Disease—PTGS2—amyotrophic lateral sclerosis	2.16e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMD1—Disease—PTGS2—amyotrophic lateral sclerosis	2.15e-05	0.000128	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.15e-05	0.000128	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.15e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMD2—Disease—PTGS2—amyotrophic lateral sclerosis	2.14e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.13e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.03e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.03e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.03e-05	0.000121	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	2.02e-05	0.00012	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	2.01e-05	0.00012	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.01e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—APOE—amyotrophic lateral sclerosis	2e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—APOE—amyotrophic lateral sclerosis	2e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—APOE—amyotrophic lateral sclerosis	2e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—APOE—amyotrophic lateral sclerosis	1.97e-05	0.000117	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.96e-05	0.000117	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	1.96e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—amyotrophic lateral sclerosis	1.9e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—amyotrophic lateral sclerosis	1.9e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—amyotrophic lateral sclerosis	1.9e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—amyotrophic lateral sclerosis	1.87e-05	0.000111	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.84e-05	0.00011	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.82e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.82e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.81e-05	0.000108	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.81e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.81e-05	0.000108	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	1.8e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.8e-05	0.000108	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.8e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.8e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.79e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.79e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.79e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.79e-05	0.000107	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	1.78e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.77e-05	0.000105	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.72e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.67e-05	9.95e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.67e-05	9.95e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.67e-05	9.95e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	1.66e-05	9.89e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.66e-05	9.89e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.65e-05	9.85e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.65e-05	9.81e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	1.65e-05	9.8e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.64e-05	9.79e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PTGS2—amyotrophic lateral sclerosis	1.63e-05	9.74e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PTGS2—amyotrophic lateral sclerosis	1.63e-05	9.74e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PTGS2—amyotrophic lateral sclerosis	1.63e-05	9.74e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PTGS2—amyotrophic lateral sclerosis	1.61e-05	9.6e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.61e-05	9.58e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.55e-05	9.25e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.52e-05	9.08e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.51e-05	9.03e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.5e-05	8.93e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	1.48e-05	8.83e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.41e-05	8.38e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.4e-05	8.35e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.4e-05	8.31e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.39e-05	8.28e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.38e-05	8.23e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.38e-05	8.23e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.38e-05	8.23e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.38e-05	8.23e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.37e-05	8.16e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.37e-05	8.16e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.37e-05	8.16e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.36e-05	8.12e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.36e-05	8.11e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.35e-05	8.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.35e-05	8.05e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.35e-05	8.04e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.32e-05	7.9e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.32e-05	7.86e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.31e-05	7.82e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.28e-05	7.63e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.27e-05	7.56e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.23e-05	7.35e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.19e-05	7.09e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.18e-05	7.06e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.18e-05	7.02e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.18e-05	7.01e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.15e-05	6.88e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.13e-05	6.75e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.09e-05	6.47e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.06e-05	6.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.06e-05	6.33e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.06e-05	6.33e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.05e-05	6.28e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.05e-05	6.24e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	1.04e-05	6.22e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.04e-05	6.19e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1e-05	5.98e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1e-05	5.98e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1e-05	5.98e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.9e-06	5.9e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.73e-06	5.8e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.26e-06	5.52e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.02e-06	5.37e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.02e-06	5.37e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.02e-06	5.37e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	8.99e-06	5.36e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	8.95e-06	5.33e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.94e-06	5.33e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.92e-06	5.32e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	8.91e-06	5.31e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	8.9e-06	5.31e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.89e-06	5.3e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.45e-06	5.03e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.2e-06	4.89e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.96e-06	4.75e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	7.36e-06	4.39e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.33e-06	4.37e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.32e-06	4.36e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.26e-06	4.33e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.22e-06	4.3e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.16e-06	4.26e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.81e-06	4.06e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.81e-06	4.06e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.81e-06	4.06e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	6.75e-06	4.02e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.73e-06	4.01e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.72e-06	4e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.67e-06	3.98e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.21e-06	3.7e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	6.02e-06	3.59e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.7e-06	3.4e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	5.54e-06	3.3e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	5.49e-06	3.27e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.04e-06	3e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.79e-06	2.85e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	4.69e-06	2.8e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.62e-06	2.75e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.4e-06	2.62e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.13e-06	2.46e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.8e-06	2.26e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.76e-06	2.24e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	3.62e-06	2.16e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.21e-06	1.92e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.48e-06	1.48e-05	CbGpPWpGaD
